Added to YB: 2026-03-10
Pitch date: 2026-03-05
TBPH [bullish]
Theravance Biopharma, Inc.
+4.59%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
Market Cap
$687.6M
Pitch Price
$13.28
Price Target
17.34 (+26%)
Dividend
N/A
EV/EBITDA
-12.82
P/E
23.38
EV/Sales
4.97
Sector
Pharmaceuticals
Category
special_situation
Theravance Biopharma: Failed Phase 3 Trial, Strategic Review
TBPH (strategic review): Phase 3 ampreloxetine trial failed, accelerating strategic review w/ Lazard (sale likely). Assets: $400M cash by Q1'26, TRELEGY milestone $100M in 2026 (highly confident, <2% sales growth needed), 35% Yupelri stake generating $45-55M annual ops income. Post-restructuring: $60-70M annual FCF from Q3'26. Irish NOLs $1.17B. Conservatively worth $17.34/share (~28% upside) at 8x ops income multiple for Yupelri. VTRS logical buyer for synergies.
Read full article (4 min)